June 18, 2025
Funny how bounces evolve into trounces and back again
While market tension escalates speculation that the U.S. will get involved in the conflict between Iran and Israel after five days ago and the there is the Fed proclamation
Breaking Econs: New housing construction hit its lowest level in five years for May. Starts ran at a seasonally adjusted annual rate of 1.256 M for the month, down 9.8% from April and the slowest since May 2020 as the economy was reeling from the Covid pandemic. Economists had been looking for 1.35 M. Building permits also slid more than expected, totaling 1.393 M off 2% from the prior month and below the 1.42 M forecast.
Initial unemployment claims for the week ending June 14 totaled a seasonally adjusted 245,000, down 5,000 from the prior week and right around the estimate for 246,000. Continuing claims, which run a week behind, nudged lower to 1.945 M, though the longer-term trend held around highs last seen in November 2021.
The Fed’s rate decision is due at 2 p.m. ET.
Pre-open Indications: 3 Sell into Strength, 1 Sell and 3 BUYs
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
June 17, 2025
Gene therapy companies are riding a new waave ...
Verve Therapeutics (VERV +$4.79 or +76.31 to $11.06) rallied after the gene editing company agreed to be acquired by Eli Lilly (LLY -$9.13 or -1.15% to $798.28) or $10.50 per share, a premium of 67.5% on the company’s last close. The deal, which is worth up to $1.3 billion, is expected to close in Q3/25.
The 2 companies were already partnered on a handful of 1-time treatments for cardiovascular diseases. VERV's leading program would use gene editing to permanently turn off the PCSK9 gene. The gene makes a protein that, when elevated, leads to high cholesterol.
LLY also agreed to pay an additional $3 per share in a contingent value right. Lilly will pay the CVR when the first patient receives Verve's leading drug in a U.S. P3 study for atherosclerotic cardiovascular disease.
June 18, 2025
Pulling the pin stuns and plumbs sentiment, dispersing share pricing after dips and flips throughout the session
As I wrote this a.m., “how long does a sector upside high last? Funny how bounces evolve into trounces and back again.”
Trader’s fingernails were bit over the latest Middle East news after bracketing the “dot plot” of Fed’s rate policy decision that kept interest rates steady amid expectations of higher inflation and lower economic growth ahead, still pointing to 2 reductions later this year, 2025
Never leave an investor uninformed!
June 17, 2025
Gene therapy companies are riding a new waave ... Verve Therapeutics (VERV +$4.79 or +76.31 to $11.06) rallied after the gene editing company agreed to be acquired by Eli Lilly (LLY -$9.13 or -1.15% to $798.28) or $10.50 per share, a premium of 67.5% on the company’s last close. The deal, which is worth up to $1.3 billion, is expected to close in Q3/25. The 2 companies were already partnered on a handful of 1-time treatments for cardiovascular diseases. VERV's leading program would use gene editing to permanently turn off the PCSK9 gene. The gene makes a protein that, when elevated, leads to high cholesterol. LLY also agreed to pay an additional $3 per share in a contingent value right. Lilly will pay the CVR when the first patient receives Verve's leading drug in a U.S. P3 study for atherosclerotic cardiovascular disease.
June 12, 2025
Newest ... 6/10/25 ... OTCQB: HRGN drops -$0.17 to $1.51 on 12 shares traded ... guess I have been right all along!! 6/4/25 ... OTCQB: HRGN... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)??? No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>. What about past (still unpaid for months of work) consultants with documentation!! Going Concern status still in effect.
May 13, 2025
SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering.
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
